Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009680 | 0.80 | PTGDR2 (0.65) | HTTPTGDR2PTGDRKMT2AMEN1 | |
| SCHEMBL21198233 | 0.79 | APP (0.53) | HTTPTGDR2KMT2AMEN1KDM4E | |
| SCHEMBL16563675 | 0.79 | SNCA (0.58) | HTTPTGDR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1578893 | 0.79 | KMT2A (0.50) | NPC1RAB9AHTTKMT2AMEN1 | |
| SCHEMBL31681587 | 0.77 | POLB (0.54) | HTTPTGDR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5106323 | 0.75 | ALDH1A1 (0.65) | HTTPTGDR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28901969 | 0.75 | PDE4B (0.51) | NPC1RAB9AKMT2AMEN1TSHR | |
| SCHEMBL24934111 | 0.74 | MTNR1A (0.50) | NPC1RAB9AHTTPTGDR2KMT2A | |
| SCHEMBL1721863 | 0.74 | KMT2A (0.49) | HTTPTGDR2KMT2AMEN1TSHR | |
| SCHEMBL16294073 | 0.74 | PTGDR2 (0.65) | PTGDR2PTGDRKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406233-B1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2406233-B1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2558094-A1 | PYRIDONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8278316-B2 | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278316-B2 | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2406233-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
| WO-2011127643-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011127643-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130086-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130086-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2010104818-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104818-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MC1R, MC5R, MCHR1 | NPC1 3104/4885RAB9A 3460/4885GSK3B 1209/4885 |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | NPC1 2759/4885RAB9A 2678/4885GSK3B 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.